Influenza viruses cause respiratory illness through a combination of direct damage to airway cells, immune-mediated inflammation, and viral strategies that evade prior immunity. The virus is an enveloped, segmented negative-sense RNA virus whose surface proteins determine how it attaches to, enters, and exits respiratory epithelial cells. Florian Krammer Icahn School of Medicine at Mount Sinai explains that these structural features both enable efficient person-to-person spread and shape the immune response that produces symptoms.
Viral entry and replication
The key viral attachment protein is hemagglutinin (HA), which binds to sialic acid residues on the surface of respiratory epithelial cells. After binding, the virus is taken into the cell by endocytosis; acidification of the endosome triggers HA-mediated membrane fusion, releasing viral ribonucleoproteins into the cytoplasm and then the nucleus for replication. Neuraminidase (NA) facilitates release of newly formed virions by cleaving sialic acids, preventing progeny from reattaching to the same cell. The segmented genome allows genetic reassortment when a cell is co-infected with different influenza strains, a mechanism implicated in the emergence of pandemic strains. Jeffrey K. Taubenberger National Institutes of Health and David M. Morens National Institutes of Health describe how reassortment and antigenic change have produced major public health events in the past century.
Host response and clinical consequences
Host innate immune sensors detect viral RNA and trigger production of interferons and proinflammatory cytokines. This immune activation limits viral replication but also produces the fever, malaise, myalgia, and airway inflammation typical of influenza. Infected epithelial cells can undergo apoptosis or necrosis, and loss of ciliary function impairs mucociliary clearance. Those effects create an environment prone to secondary bacterial infection, which is a common reason influenza progresses from an uncomplicated upper respiratory illness to pneumonia and severe disease. Seasonal epidemiology and population vulnerability matter: infants, older adults, pregnant people, and individuals with chronic cardiopulmonary disease are at higher risk of severe complications.
Antigenic drift (accumulation of point mutations in HA and NA) drives annual epidemics by reducing the effectiveness of existing antibodies, while antigenic shift (reassortment producing a novel HA or NA) can generate strains with little preexisting immunity and cause pandemics. These evolutionary dynamics explain why vaccines are updated regularly and why community-level factors like vaccine coverage, household crowding, and care-seeking behavior shape local impact. The World Health Organization and national health agencies monitor circulating strains to inform vaccine composition and public health measures.
Environmental and cultural nuances alter influenza’s footprint: temperate regions show strong winter seasonality, while tropical regions often see year-round transmission with peaks tied to rainfall or social patterns. Antiviral drugs target viral proteins—neuraminidase inhibitors reduce replication if given early, whereas resistance and limited therapeutic windows can constrain effectiveness. Understanding the interplay of viral mechanisms, host responses, and population context is essential for prevention, clinical management, and public health planning.